Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 First FDA Approval Agnostic of Cancer Site

× No keyword cloud information.

197 in total

1. Low clinical adoption of tumor genomic profiling: cause for concern?

Authors: Michael W Drazer; Randy F Sweis
Journal: J Med Econ Date: 2018-05-15 Impact factor: 2.448

2. High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients.

Authors: Dedong Cao; Huilin Xu; Ximing Xu; Tao Guo; Wei Ge
Journal: Oncoimmunology Date: 2019-06-16 Impact factor: 8.110

Review 3. Update on Genetic Testing in Gynecologic Cancer.

Authors: Susan M Domchek; Mark E Robson
Journal: J Clin Oncol Date: 2019-08-12 Impact factor: 44.544

Review 4. Implementing tumor mutational burden (TMB) analysis in routine diagnostics-a primer for molecular pathologists and clinicians.

Authors: Michael Allgäuer; Jan Budczies; Petros Christopoulos; Volker Endris; Amelie Lier; Eugen Rempel; Anna-Lena Volckmar; Martina Kirchner; Moritz von Winterfeld; Jonas Leichsenring; Olaf Neumann; Stefan Fröhling; Roland Penzel; Michael Thomas; Peter Schirmacher; Albrecht Stenzinger
Journal: Transl Lung Cancer Res Date: 2018-12

Review 5. [Pancreatic ductal adenocarcinoma].

Authors: E Gallmeier; T M Gress
Journal: Internist (Berl) Date: 2018-08 Impact factor: 0.743

6. Twenty Years with Personalized Medicine: Past, Present, and Future of Individualized Pharmacotherapy.

Authors: Jan Trøst Jørgensen
Journal: Oncologist Date: 2019-04-02

Review 7. Immunotherapy: Checkpoint Inhibitors in Lynch-Associated Gynecologic Cancers.

Authors: J Stuart Ferriss; M Yvette Williams-Brown
Journal: Curr Treat Options Oncol Date: 2019-08-23

8. Biomarkers in chronic graft-versus-host disease: quo vadis?

Authors: D Wolff; H Greinix; S J Lee; T Gooley; S Paczesny; S Pavletic; F Hakim; F Malard; M Jagasia; A Lawitschka; J A Hansen; D Pulanic; E Holler; A Dickinson; E Weissinger; M Edinger; S Sarantopoulos; K R Schultz
Journal: Bone Marrow Transplant Date: 2018-01-24 Impact factor: 5.483

Review 9. TRK Inhibition: A New Tumor-Agnostic Treatment Strategy.

Authors: Shivaani Kummar; Ulrik N Lassen
Journal: Target Oncol Date: 2018-10 Impact factor: 4.493

10. Ovarian Carcinoma Histotype: Strengths and Limitations of Integrating Morphology With Immunohistochemical Predictions.

Authors: Martin Köbel; Li Luo; Xin Grevers; Sandra Lee; Angela Brooks-Wilson; C Blake Gilks; Nhu D Le; Linda S Cook
Journal: Int J Gynecol Pathol Date: 2019-07 Impact factor: 2.762

First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication.